Panelists discuss how familial chylomicronemia syndrome (FCS) is diagnosed and managed, emphasizing the role of early intervention in preventing severe complications and exploring current and emerging RNA interference–based therapies, such as APOC3 and ANGPTL3 inhibitors, which offer new avenues for effective triglyceride control and potential improvements in patient outcomes.
Panelists discuss how familial chylomicronemia syndrome (FCS) is characterized by severe hypertriglyceridemia and genetic mutations in the LPL gene, highlighting the key diagnostic criteria and complications, such as acute pancreatitis, while emphasizing the impact of untreated FCS on patient quality of life and long-term health risks.
Watch
EP. 2: Quality of Life and Diagnostic Considerations for FCS
September 23rd 2024Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.
Watch